The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cancer risk of pathogenic germline variants among 164,774 adult cancers.
 
Jie Liu
No Relationships to Disclose
 
Seth Wallerstein
No Relationships to Disclose
 
Michael Conry
No Relationships to Disclose
 
Liying Xue
No Relationships to Disclose
 
Duc Tran
No Relationships to Disclose
 
Xiaoyu Zong
No Relationships to Disclose
 
Li Ding
No Relationships to Disclose
 
Yelena Kemel
No Relationships to Disclose
 
Vignesh Ravichandran
No Relationships to Disclose
 
Semanti Mukherjee
No Relationships to Disclose
 
Ramaswamy Govindan
No Relationships to Disclose
 
Yin Cao
No Relationships to Disclose
 
Paul Pharoah
Patents, Royalties, Other Intellectual Property - The PREDICT breast cancer prognostic model is licensed to OncoAssist by the University of Cambridge. I receive a share of the fees.
Expert Testimony - Shook, Hardy, Bcon
 
Vijai Joseph
No Relationships to Disclose
 
Pradeep Natarajan
Employment - Vertex (I)
Stock and Other Ownership Interests - Bolt Biotherapeutics; Candela; Mercury; Parameter Health; Preciseli; TenSixteen Bio; Vertex (I)
Consulting or Advisory Role - Allelica; Apple; AstraZeneca; Bain Capital; Blackstone; Bristol-Myers Squibb; crispr therapeutics; Esperion Therapeutics; Foresite Capital; Foresite Capital; Foresite Capital; Genentech/Roche; GV; HeartFlow; Lilly; Magnet Biomedicine; Novartis; Novo Nordisk; TenSixteen Bio; Tourmaline Bio
Research Funding - AstraZeneca; Genentech; Novartis
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Kelly Bolton
Consulting or Advisory Role - SERVIER
Research Funding - Bristol Myers Squibb Foundation; SERVIER